- Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline.
- AUTO1 has entered a pivotal trial for ALL and may achieve regulatory approval by 2022, while, for AUTO3, an outpatient cohort has been initiated in DLBCL.
- Both lead assets have shown promising data with best-in-class potential as they address key toxicity issues observed with other T cell therapies, while demonstrating durable complete responses.
- The stock has fallen significantly from all-time highs, but short to medium-term catalysts may breath life into the fundamental story again.
- Expect clinical updates for AUTO1 in ALL, as well as for AUTO3 in DLBCL at ASH in early December.
For further details see:
Autolus: Short To Medium-Term Clinical Catalysts May Drive Stock Price Upside